0
POPSMyriad Genetics Rebounds This speaks volumes about the way many investors felt about Myriad's Alzheimer's drug development program. The drug, Flurizan, failed yesterday. Shares dutifully fell. But today they ramped up to a level before the failure. This makes sense, because the drug development program was high risk, and was a drag on the company's genetic testing business. Now, investors can bet on a genomics and diagnostics company without worrying that a risky Alzheimer's drug is about to fail.
Clips
Latest Pops
Latest Comments
Most Pops
Tags
Print
Save
Turn on live update